Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-10-09
2007-10-09
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S138100, C530S387100, C530S388220, C530S388800, C530S350000, C530S388850
Reexamination Certificate
active
10281479
ABSTRACT:
An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
REFERENCES:
patent: 6072047 (2000-06-01), Rauch et al.
patent: 6252050 (2001-06-01), Ashkenazi et al.
patent: 6294546 (2001-09-01), Rosen et al.
patent: 6313269 (2001-11-01), Deen et al.
patent: 6342363 (2002-01-01), Ni et al.
patent: 6342369 (2002-01-01), Ashkenazi
patent: 6433147 (2002-08-01), Ni et al.
patent: 6461823 (2002-10-01), Ni et al.
patent: 6534061 (2003-03-01), Goddard et al.
patent: 6635482 (2003-10-01), Yu et al.
patent: 6872568 (2005-03-01), Ni et al.
patent: 7105640 (2006-09-01), Desnoyers et al.
patent: 2002/0072091 (2002-06-01), Ni et al.
patent: 2002/0098550 (2002-07-01), Ni et al.
patent: 2003/0228309 (2003-12-01), Salcedo et al.
patent: WO 90/07861 (1990-07-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 98/46643 (1998-10-01), None
patent: WO 98/51793 (1998-11-01), None
patent: WO 99/02653 (1999-01-01), None
patent: WO 99/03992 (1999-01-01), None
patent: WO 99/09165 (1999-02-01), None
patent: WO 99/09165 (1999-02-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/12963 (1999-03-01), None
patent: WO 99/37684 (1999-07-01), None
patent: WO 00/66156 (2000-11-01), None
patent: WO 00/67793 (2000-11-01), None
patent: WO 00/73349 (2000-12-01), None
patent: WO 01/83560 (2001-11-01), None
patent: WO 02/079377 (2002-10-01), None
Czuczman et al., Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy, J. Clin. Oncol. 17(1):268-276, Jan. 1999.
Basic and Clinical Immuology (1994) 8th Ed., Stites et al. editors, (Appleton & Lange:Norwalk CT), p. 137.
Srivastava, TRAIL/Apo-2L:Mechanisms and clinical applications in cancer, Neoplasia, 3(6):535-546, 2001.
Arai et al., Cancer Lett. 133(2):197-204 (Nov. 27, 1998).
Ashkenzai et al., Safety and antitumor activity of recombinant soluble Apo2 ligand, J. Clin. Invest. 104:155-62 (1999).
Bendele et al., Clin Exp. Rheumatol. 17(5):553-560 (1999).
Berckmans et al., Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism, Arthritis Rheum. 46(11):2857-66 (Nov. 2002).
Bodmer et al., TRAIL receptor-2 signals apoptosis through FADD and caspase-8, Nat. Cell Biol. 2:241-3 (2000).
Bonavida et al. “Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics (Review),”Int J Oncol. 15: 793-802 (1999).
Chaudhary et al. “Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway”ImmunityDec.;7(6): 821-30 (1997).
Chinnaiyan et al., “Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy,”Proc. Natl. Acad. Sci., Feb. 15 97(4):1754-1759 (2000).
Choy et al., Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-t receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial, Arthritis Rheum. 46(12):3143-50 (Dec. 2002).
Chuntharapai et al. “Isotype-Dependent Inhibition of Tumor Growth in Vivo by Monoclonal Antibodies to Death Receptor 4,”J. Immunol. 166:4891-4898 (2001).
Ciranni et al., The “Braids Lady” of Arezzo: a case of rheumatoid arthritis in a 16thcentury mummy, Clin. Exp. Rheumatol 20(6):745-52 (Nov.-Dec. 2002).
Clarke et al., “Reovirus-Induced Apoptosis Is Mediated by TRAIL,”J. Virol. Sep. 74(17):8135-8139 (2000).
Degli-Esposti et al “Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family”J. Exp MedDec.; 186(7):1165-1170 (1997).
Degli-Eposti et al., The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL mediated apoptosis, yet reatains an incomplete death domain, Immunity 7:813-20 (1997).
Emery et al., “Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL,”J Biol ChemJun. 5;273(23):146363-7 (1998).
Fanger et al. “Human Dendritic Cells Mediate Cellular Apoptosis via Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)”J Exp MedOct. 18;190(8):1155-64 (1999).
Fujisawa et al., “Therapeutic Effect of the Anti-Fas Antibody on Arthritis in HTLV-I tax Transgenic Mice,”J. Clin. Invest. 98(2): 271-278 (1996).
Griffith et al. “Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies,”J. Immunol162: 2597-2605 (1999).
Herr et al., JNK/SAPK activity contributes to TRAIL-induced apoptosis, Cell Death Differ 6:130-5 (1999).
Ichikawa et al. “Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity,”Nature Med. Aug. 7(8): 954-960 (2001).
Jeremias et al., TRAIL induces apoptosis and activation of NF-kappaB, Eur. Cytokine Netw. 9:687-8 (1998).
Jo et al., Apoptosis induced in normal human hepatocytes by tumor necrosis factor related apoptosis inducing ligand,Nat. Med. 6:564-7 (2000).
Keane et al. “Chemotherapy Augments TRAIL-induced Apoptosis in Breast Cell Lines,”Cancer Res. Feb. 1 59: 734-741(1999).
Kischkel et al., Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5, Immunity 12:611-20 (2000).
Kuang et al., FADD is required for DR4- and DR5- mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts, J. Biol. Chem. 275:25065-8 (2000).
Lee et al. “Alterations ofDR5/TRAIL Receptor 2Gene in Non-Small Lung Cancer”Cancer Res. Nov. 15 59: 5683-6 (1999).
Lindblad et al., Patients' view of priority setting for new medicines. A qualitative study of patients with rheumatoid arthritis, Scan. J. Rheumatol. 31(6):324-9 (2002).
MacFarlane et al. “Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL,”J Biol ChemOct. 10;272(41):25417-20 (1997).
Madland et al., Leukocyte protein calprotectin and outcome in rheumatoid arthritis. A longitudinal study, Scand. J. Rheumatol. 31(6):351-4 (2002).
Marsters et al. “A novel receptor for Apo2L/TRAIL contains a truncated death domain”Curr BiolDec. 1;7(12):1003-6 (1997).
Merkesdal et al., Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with reheumatoid arthritis, Z. Rheumatol. 61 Suppl. 2:II29-II32 (2002).
Mitsiades et al. “Ewing's Sarcoma Family Tumors Are Sensitive to Tumor Necrosis Factor-related Apoptosis-inducing Ligand and Express Death Receptor 4 and Death Receptor 5”Cancer ResMar. 15;61:2704-12 (2001).
Mizutani et al. “Synergistic Cytotoxicity and Apoptosis by Apo-2 Ligand and Adriamycin against Bladder Cancer Cells”Clin Cancer Res. Sep.;5:2605-12 (1999).
Muhlenbeck et al., TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways, J. Biol. Chem. 273:33091-8 (1998).
Pan et al. “The receptor for the cytotoxic ligand TRAIL”ScienceApr. 4;276(5309):111-3 (1997).
Pan et al. “An antagonist decoy receptor and a death domain-containing receptor for TRAIL”ScienceAug. 8;277(5327):815-818 (1997).
Reichel et al. Radiological changes in the cervical spine in rheumatoid arthritis—prognostic factors obtained by a cross-sectional study, Z. Rheumatol. 61(6):710-7 (Dec. 2000).
Schneider et al. “TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB”ImmunityDec.;7(6): 831-836 (1997).
Seitz et al., Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum fr
Buchsbaum Donald J.
Ichikawa Kimihisa
Kimberly Robert P.
Koopman William J.
Lobuglio Albert F.
Fish & Richardson P.C.
Kaufman Claire M.
Spector Lorraine
The UAB Research Foundation
LandOfFree
Combinations of DR5 antibodies and other therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations of DR5 antibodies and other therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of DR5 antibodies and other therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3834562